特一药业 (002728)

TEYI PHARMACEUTICAL GROUP CO.,LTD

ASZ

Tags

Nicotinamide Mononucleotide (NMN) ConceptMedical Aesthetics ConceptFund Exclusive HoldingsSmall Cap Non-FinancialHelicobacter PyloriChinese Med. IISZSE Medicine Equal Weight IndexShenzhen A-Share Pharmaceutical IndexCSI All-share Pharmaceutical Sector IndexSZSE Performance IndexNew Virus PreventionCOVID-19 PreventionStocks Below Placement PriceConvertible Bond IssuersSME Board Composite IndexSZSE Selected IndexChina United Quality Growth IndexPrivate Enterprise Development IndexPharmaceutical & Health 100 IndexHigh Dividend Yield Strategy IndexSME Board Dividend IndexCICC 300 IndexSZSE Dividend 50 IndexGuangdong

K-Line Chart

No K-line data available

Company NameTeyi Pharmaceutical Group Co., Ltd.
Listing Date2014-07-31
Issue Price14RMB
Registered Capital51256.543410k RMB
Legal RepresentativeXu Ronghuang
Registered AddressNo. 9, 11 Changxing Road, Taicheng, Taishan City, Guangdong Province
IndustryTraditional Chinese Medicine II
Main BusinessMainly engaged in the research and development, production, and sales of Chinese patent medicines and chemical preparations.
Company ProfileTeyi Pharmaceutical Group Co., Ltd. (referred to as Teyi Pharmaceutical) is a listed pharmaceutical company (SZSE stock code: 002728) integrating pharmaceutical R&D, pharmaceutical manufacturing, and pharmaceutical commerce. Its subsidiaries are located in Guangdong, Hainan, Anhui, and other regions. Teyi Pharmaceutical and its wholly-owned subsidiaries, Hainan Haili Pharmaceutical Co., Ltd. and Taishan Xinning Pharmaceutical Co., Ltd., are all National High-Tech Enterprises. Teyi Pharmaceutical has been successively recognized as "Outstanding Contribution Enterprise in Guangdong Pharmaceutical Industry", "Guangdong Private Technology Enterprise", "Top 10 Comprehensive Strength Pharmaceutical Industrial Enterprises in Guangdong Province for 2015", "Guangdong Private Enterprise Innovation Industrialization Demonstration Base", "No. 56 in Top 100 Chinese Traditional Chinese Medicine Enterprises for 2018", "Guangdong Innovative Enterprise", "Contract-Honoring and Credit-Worthy Enterprise", "Grade A Taxpayer", "AAA Credit Rating Customer", "Top 100 Taxpayer Enterprise", "Top 500 Manufacturing Enterprises in Guangdong Province for 2014", etc. Teyi Pharmaceutical's wholly-owned subsidiary, Hainan Haili Pharmaceutical Co., Ltd., has been successively recognized as "National Intellectual Property Advantage Enterprise for 2018", "Top 10 Integrity Units in Hainan Pharmaceutical Industry", "Top 10 Benchmark Enterprises for Standardized Management in Hainan Industrial Economy", "National AAA-Level Enterprise for Quality, Service, and Reputation", and "Grade A Taxpayer", etc.

Stock Details

1. Key Indicators

  • Total Shares(W): 51266.19
  • Circulating A-Shares(W): 37647.37
  • Earnings Per Share(RMB): 0.1300
  • Net Assets Per Share(RMB): 3.5168
  • Operating Revenue(W RMB): 69185.06
  • Total Profit(W RMB): 7483.27
  • Net Profit Attributable to Parent(W RMB): 6521.71
  • Net Profit Growth Rate(%): 985.18
  • Weighted Return on Equity(%): 3.6500
  • Operating Cash Flow Per Share(RMB): 0.3730
  • Undistributed Profit Per Share(RMB): 0.7681
  • Capital Reserve Per Share(RMB): 1.6546

2. Main Business

The main business covers:

  • Research, production and sales of Chinese patent medicines
  • Research, production and sales of chemical preparation drugs
  • Research, production and sales of chemical raw materials

3. Company Basic Information

  • Company Name: Teyi Pharmaceutical Group Co., Ltd.
  • Listing Date: 2014-07-31
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 9, 11 Changxing Road, Taicheng, Taishan City, Guangdong Province, China
  • Website: www.tczy.com.cn
  • Company Profile：The company was established by the overall change of Taicheng Co., Ltd. into a joint stock company. The promoters were 24 natural persons including Xu Danqing, Xu Weigao, Xu Songqing, Xu Hengqing, Xu Lifang, Zhao Ruisheng and Chen Xiliang. The company converted the total audited net assets of Taicheng Co., Ltd. as of April 30, 2009, amounting to 86,119,500.9 yuan, into 69 million shares. The balance of 17,119,500.9 yuan was recorded as capital reserve. The company completed the industrial and commercial change registration at the Jiangmen Administration for Industry and Commerce on June 24, 2009, and obtained the "Business License of Enterprise Legal Person" with registration number 440781000013044, with a registered capital of 69 million yuan.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Xingquan CSI 800 Six-Month Holding Index Enhanced Securities Investment Fund Class A Fund 333.38 0.89
2 Xingquan CSI 300 Index Enhanced Securities Investment Fund (LOF) Class A Fund 192.02 0.51
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 136.96 0.36

5. Concept Sectors

  • Medical Aesthetics Concept
  • NMN Concept
  • Helicobacter Pylori Concept
  • Hepatitis Concept
  • Fund Exclusive
  • Recently Weak
  • Small Cap Non-Margin

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information